Search Medical Condition
Please enter condition
Please choose location

Saint-Herblain Cedex, France Clinical Trials

A listing of Saint-Herblain Cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (353) clinical trials

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

Gastrointestinal stromal tumours (GISTs) are rare mesenchymal neoplasms, mostly diagnosed between 55 and 60 years of age, which account for 5% of all sarcomas. Worldwide annual incidence is approximately 12 cases per million people, corresponding to approximately 800 new cases per year in France. A large majority of GISTs harbour ...

Phase

0.0 miles

Learn More »

Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

PRIMARY OBJECTIVES: I. To evaluate the antitumor activity of cabozantinib-s-malate (cabozantinib) for Ewing sarcomas, in terms of 6-month objectives response as per the Response Evaluation Criteria in Solid Tumors, Revised (RECIST version [v]1.1). II. To evaluate the antitumor activity of cabozantinib for osteosarcoma, in terms of 6-month objective response (complete ...

Phase

0.0 miles

Learn More »

Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD

Inclusion of ADPKD patients in 20 different centers of Nephrology in the Western part of France Characterization of the Phenotype Collect DNA sample Analysis of PKD1 and PKD2 genes first Analysis of HNFIb and UMOD for PKD1 and PKD2 negative patients Recruitment of affected and non-affected relatives of PKD1 and ...

Phase N/A

0.0 miles

Learn More »

A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

METHODOLOGY Randomized, placebo-controlled, multicentric, phase II study -This is a double-blind placebo-controlled trial, with 4 cohort: cohort A: Osteosarcoma cohort B: Ewing sarcoma cohort C: Chondrosarcoma cohort D : chondroma. Cohort A, B and C will involve a total of 36 patients (24 Regorafenib + 12 placebo). And cohort D ...

Phase

0.0 miles

Learn More »

A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

French national multicentric phase III trial evaluating chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma

Phase

0.0 miles

Learn More »

Platine Avastin and OLAparib in 1st Line

Patients with advanced FIGO stage IIIB - IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance.

Phase

0.0 miles

Learn More »

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

The EXTREME regimen, i.e. cetuximab added to platinum (100 mg/m every 3 weeks ) and 5FU (96h continuous infusion at 1000 mg/m/day every 3 weeks) during 6 cycles of treatment and continued as maintenance in patients with stable disease, is currently the standard of care in first line recurrent metastatic ...

Phase

0.0 miles

Learn More »

A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.

This is a phase II/III, multicenter, randomized study which includes 420 patients on six years + 3 years follow up. 92 patients will be included during the phase II ; additional 328 patients will be included. Patients with an advanced or metastatic urothelial cancer with impaired renal function will be ...

Phase

0.0 miles

Learn More »

Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

This is a prospective, non-randomized and multicenter study designed to compare biological features between pN0 triple negative breast cancer (TNBC) with size 10 mm (pT1a/b) versus pT1c T2 30 mm. All consecutive patients will be recruited by each investigator after completion of surgery. No modification of standard management according to ...

Phase N/A

0.0 miles

Learn More »

Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose

For the specific patient population studied receiving 5-Fluorouracil, epirubicin and cyclophosphamide - Docetaxel sequence (cumulative dose <300 mg / m2), using a cryoprotection has never been assessed. The effectiveness of cryoprotection of onycholysis secondary to Docetaxel is not well established in this population (breast cancer in the adjuvant setting) and ...

Phase N/A

0.0 miles

Learn More »